aluates Reports

$ 0.0

Automative

Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-18H13280

Global Ventilator Associated Pneumonia VAP Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Research Report 2025

Code: QYRE-Auto-18H13280

Report

September 2025

Pages:103

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Ventilator Associated Pneumonia (VAP) Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Ventilator Associated Pneumonia (VAP) Therapeutics Market

The global market for Ventilator Associated Pneumonia (VAP) Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Ventilator Associated Pneumonia (VAP) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ventilator Associated Pneumonia (VAP) Therapeutics.

The Ventilator Associated Pneumonia (VAP) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Ventilator Associated Pneumonia (VAP) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Ventilator Associated Pneumonia (VAP) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Ventilator Associated Pneumonia (VAP) Therapeutics Market Report

Report Metric	Details
Report Name	Ventilator Associated Pneumonia (VAP) Therapeutics Market
CAGR	5%
Segment by Type	Prevention Physiotherapy Immunity Therapy
Segment by Application	Hospitals Ambulatory Surgical Center Diagnostic Centers
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Achaogen, Adenium Biotech, Aridis Pharmaceuticals, AstraZeneca, Bayer, Cardeas Pharma, Destiny Pharma, Dong-A Socio Holdings, Lakewood-Amedex, MedImmune, Meiji Seika Pharma, Merck & Co, Motif Bio, Nabriva Therapeutics, Polyphor, Shionogi & Co, Tetraphase Pharmaceuticals, The Medicines Company, Theravance Biopharma, Wockhardt, Zavante Therapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ventilator Associated Pneumonia (VAP) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Ventilator Associated Pneumonia (VAP) Therapeutics Market report?

Ans: The main players in the Ventilator Associated Pneumonia (VAP) Therapeutics Market are Achaogen, Adenium Biotech, Aridis Pharmaceuticals, AstraZeneca, Bayer, Cardeas Pharma, Destiny Pharma, Dong-A Socio Holdings, Lakewood-Amedex, MedImmune, Meiji Seika Pharma, Merck & Co, Motif Bio, Nabriva Therapeutics, Polyphor, Shionogi & Co, Tetraphase Pharmaceuticals, The Medicines Company, Theravance Biopharma, Wockhardt, Zavante Therapeutics

What are the Application segmentation covered in the Ventilator Associated Pneumonia (VAP) Therapeutics Market report?

Ans: The Applications covered in the Ventilator Associated Pneumonia (VAP) Therapeutics Market report are Hospitals, Ambulatory Surgical Center, Diagnostic Centers

What are the Type segmentation covered in the Ventilator Associated Pneumonia (VAP) Therapeutics Market report?

Ans: The Types covered in the Ventilator Associated Pneumonia (VAP) Therapeutics Market report are Prevention, Physiotherapy, Immunity Therapy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Prevention

1.2.3 Physiotherapy

1.2.4 Immunity Therapy

1.3 Market by Application

1.3.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Ambulatory Surgical Center

1.3.4 Diagnostic Centers

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Perspective (2020-2031)

2.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Growth Trends by Region

2.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Dynamics

2.3.1 Ventilator Associated Pneumonia (VAP) Therapeutics Industry Trends

2.3.2 Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers

2.3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges

2.3.4 Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue

3.1.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue

3.4 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio

3.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2024

3.5 Global Key Players of Ventilator Associated Pneumonia (VAP) Therapeutics Head office and Area Served

3.6 Global Key Players of Ventilator Associated Pneumonia (VAP) Therapeutics, Product and Application

3.7 Global Key Players of Ventilator Associated Pneumonia (VAP) Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type

4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2026-2031)

5 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application

5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2020-2031)

6.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2020-2025)

6.4 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2020-2031)

7.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2020-2025)

7.4 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2020-2031)

9.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Achaogen

11.1.1 Achaogen Company Details

11.1.2 Achaogen Business Overview

11.1.3 Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.1.4 Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.1.5 Achaogen Recent Development

11.2 Adenium Biotech

11.2.1 Adenium Biotech Company Details

11.2.2 Adenium Biotech Business Overview

11.2.3 Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.2.4 Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.2.5 Adenium Biotech Recent Development

11.3 Aridis Pharmaceuticals

11.3.1 Aridis Pharmaceuticals Company Details

11.3.2 Aridis Pharmaceuticals Business Overview

11.3.3 Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.3.4 Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.3.5 Aridis Pharmaceuticals Recent Development

11.4 AstraZeneca

11.4.1 AstraZeneca Company Details

11.4.2 AstraZeneca Business Overview

11.4.3 AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.4.4 AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.4.5 AstraZeneca Recent Development

11.5 Bayer

11.5.1 Bayer Company Details

11.5.2 Bayer Business Overview

11.5.3 Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.5.4 Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.5.5 Bayer Recent Development

11.6 Cardeas Pharma

11.6.1 Cardeas Pharma Company Details

11.6.2 Cardeas Pharma Business Overview

11.6.3 Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.6.4 Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.6.5 Cardeas Pharma Recent Development

11.7 Destiny Pharma

11.7.1 Destiny Pharma Company Details

11.7.2 Destiny Pharma Business Overview

11.7.3 Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.7.4 Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.7.5 Destiny Pharma Recent Development

11.8 Dong-A Socio Holdings

11.8.1 Dong-A Socio Holdings Company Details

11.8.2 Dong-A Socio Holdings Business Overview

11.8.3 Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.8.4 Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.8.5 Dong-A Socio Holdings Recent Development

11.9 Lakewood-Amedex

11.9.1 Lakewood-Amedex Company Details

11.9.2 Lakewood-Amedex Business Overview

11.9.3 Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.9.4 Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.9.5 Lakewood-Amedex Recent Development

11.10 MedImmune

11.10.1 MedImmune Company Details

11.10.2 MedImmune Business Overview

11.10.3 MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.10.4 MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.10.5 MedImmune Recent Development

11.11 Meiji Seika Pharma

11.11.1 Meiji Seika Pharma Company Details

11.11.2 Meiji Seika Pharma Business Overview

11.11.3 Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.11.4 Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.11.5 Meiji Seika Pharma Recent Development

11.12 Merck & Co

11.12.1 Merck & Co Company Details

11.12.2 Merck & Co Business Overview

11.12.3 Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.12.4 Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.12.5 Merck & Co Recent Development

11.13 Motif Bio

11.13.1 Motif Bio Company Details

11.13.2 Motif Bio Business Overview

11.13.3 Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.13.4 Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.13.5 Motif Bio Recent Development

11.14 Nabriva Therapeutics

11.14.1 Nabriva Therapeutics Company Details

11.14.2 Nabriva Therapeutics Business Overview

11.14.3 Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.14.4 Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.14.5 Nabriva Therapeutics Recent Development

11.15 Polyphor

11.15.1 Polyphor Company Details

11.15.2 Polyphor Business Overview

11.15.3 Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.15.4 Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.15.5 Polyphor Recent Development

11.16 Shionogi & Co

11.16.1 Shionogi & Co Company Details

11.16.2 Shionogi & Co Business Overview

11.16.3 Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.16.4 Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.16.5 Shionogi & Co Recent Development

11.17 Tetraphase Pharmaceuticals

11.17.1 Tetraphase Pharmaceuticals Company Details

11.17.2 Tetraphase Pharmaceuticals Business Overview

11.17.3 Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.17.4 Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.17.5 Tetraphase Pharmaceuticals Recent Development

11.18 The Medicines Company

11.18.1 The Medicines Company Company Details

11.18.2 The Medicines Company Business Overview

11.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.18.4 The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.18.5 The Medicines Company Recent Development

11.19 Theravance Biopharma

11.19.1 Theravance Biopharma Company Details

11.19.2 Theravance Biopharma Business Overview

11.19.3 Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.19.4 Theravance Biopharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.19.5 Theravance Biopharma Recent Development

11.20 Wockhardt

11.20.1 Wockhardt Company Details

11.20.2 Wockhardt Business Overview

11.20.3 Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.20.4 Wockhardt Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.20.5 Wockhardt Recent Development

11.21 Zavante Therapeutics

11.21.1 Zavante Therapeutics Company Details

11.21.2 Zavante Therapeutics Business Overview

11.21.3 Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction

11.21.4 Zavante Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

11.21.5 Zavante Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

Table 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Prevention

Table 3. Key Players of Physiotherapy

Table 4. Key Players of Immunity Therapy

Table 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2020-2025)

Table 9. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2026-2031)

Table 11. Ventilator Associated Pneumonia (VAP) Therapeutics Market Trends

Table 12. Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers

Table 13. Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges

Table 14. Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints

Table 15. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players (2020-2025)

Table 17. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2024)

Table 18. Ranking of Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Ventilator Associated Pneumonia (VAP) Therapeutics, Headquarters and Area Served

Table 21. Global Key Players of Ventilator Associated Pneumonia (VAP) Therapeutics, Product and Application

Table 22. Global Key Players of Ventilator Associated Pneumonia (VAP) Therapeutics, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2020-2025)

Table 26. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2026-2031)

Table 28. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2020-2025)

Table 30. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2026-2031)

Table 32. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 47. Achaogen Company Details

Table 48. Achaogen Business Overview

Table 49. Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 50. Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 51. Achaogen Recent Development

Table 52. Adenium Biotech Company Details

Table 53. Adenium Biotech Business Overview

Table 54. Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 55. Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 56. Adenium Biotech Recent Development

Table 57. Aridis Pharmaceuticals Company Details

Table 58. Aridis Pharmaceuticals Business Overview

Table 59. Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 60. Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 61. Aridis Pharmaceuticals Recent Development

Table 62. AstraZeneca Company Details

Table 63. AstraZeneca Business Overview

Table 64. AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 65. AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 66. AstraZeneca Recent Development

Table 67. Bayer Company Details

Table 68. Bayer Business Overview

Table 69. Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 70. Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 71. Bayer Recent Development

Table 72. Cardeas Pharma Company Details

Table 73. Cardeas Pharma Business Overview

Table 74. Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 75. Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 76. Cardeas Pharma Recent Development

Table 77. Destiny Pharma Company Details

Table 78. Destiny Pharma Business Overview

Table 79. Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 80. Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 81. Destiny Pharma Recent Development

Table 82. Dong-A Socio Holdings Company Details

Table 83. Dong-A Socio Holdings Business Overview

Table 84. Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 85. Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 86. Dong-A Socio Holdings Recent Development

Table 87. Lakewood-Amedex Company Details

Table 88. Lakewood-Amedex Business Overview

Table 89. Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 90. Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 91. Lakewood-Amedex Recent Development

Table 92. MedImmune Company Details

Table 93. MedImmune Business Overview

Table 94. MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 95. MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 96. MedImmune Recent Development

Table 97. Meiji Seika Pharma Company Details

Table 98. Meiji Seika Pharma Business Overview

Table 99. Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 100. Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 101. Meiji Seika Pharma Recent Development

Table 102. Merck & Co Company Details

Table 103. Merck & Co Business Overview

Table 104. Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 105. Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 106. Merck & Co Recent Development

Table 107. Motif Bio Company Details

Table 108. Motif Bio Business Overview

Table 109. Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 110. Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 111. Motif Bio Recent Development

Table 112. Nabriva Therapeutics Company Details

Table 113. Nabriva Therapeutics Business Overview

Table 114. Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 115. Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 116. Nabriva Therapeutics Recent Development

Table 117. Polyphor Company Details

Table 118. Polyphor Business Overview

Table 119. Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 120. Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 121. Polyphor Recent Development

Table 122. Shionogi & Co Company Details

Table 123. Shionogi & Co Business Overview

Table 124. Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 125. Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 126. Shionogi & Co Recent Development

Table 127. Tetraphase Pharmaceuticals Company Details

Table 128. Tetraphase Pharmaceuticals Business Overview

Table 129. Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 130. Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 131. Tetraphase Pharmaceuticals Recent Development

Table 132. The Medicines Company Company Details

Table 133. The Medicines Company Business Overview

Table 134. The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 135. The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 136. The Medicines Company Recent Development

Table 137. Theravance Biopharma Company Details

Table 138. Theravance Biopharma Business Overview

Table 139. Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 140. Theravance Biopharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 141. Theravance Biopharma Recent Development

Table 142. Wockhardt Company Details

Table 143. Wockhardt Business Overview

Table 144. Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 145. Wockhardt Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 146. Wockhardt Recent Development

Table 147. Zavante Therapeutics Company Details

Table 148. Zavante Therapeutics Business Overview

Table 149. Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Product

Table 150. Zavante Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025) & (US$ Million)

Table 151. Zavante Therapeutics Recent Development

Table 152. Research Programs/Design for This Report

Table 153. Key Data Information from Secondary Sources

Table 154. Key Data Information from Primary Sources

Table 155. Authors List of This Report

List of Figures

Figure 1. Ventilator Associated Pneumonia (VAP) Therapeutics Picture

Figure 2. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Prevention Features

Figure 5. Physiotherapy Features

Figure 6. Immunity Therapy Features

Figure 7. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2024 VS 2031

Figure 9. Hospitals Case Studies

Figure 10. Ambulatory Surgical Center Case Studies

Figure 11. Diagnostic Centers Case Studies

Figure 12. Ventilator Associated Pneumonia (VAP) Therapeutics Report Years Considered

Figure 13. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region: 2024 VS 2031

Figure 16. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players in 2024

Figure 17. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2024

Figure 19. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2020-2031)

Figure 21. United States Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2020-2031)

Figure 25. Germany Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2020-2031)

Figure 33. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2020-2031)

Figure 41. Mexico Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2020-2031)

Figure 45. Turkey Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Achaogen Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 49. Adenium Biotech Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 50. Aridis Pharmaceuticals Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 51. AstraZeneca Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 52. Bayer Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 53. Cardeas Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 54. Destiny Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 55. Dong-A Socio Holdings Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 56. Lakewood-Amedex Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 57. MedImmune Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 58. Meiji Seika Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 59. Merck & Co Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 60. Motif Bio Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 61. Nabriva Therapeutics Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 62. Polyphor Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 63. Shionogi & Co Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 64. Tetraphase Pharmaceuticals Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 65. The Medicines Company Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 66. Theravance Biopharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 67. Wockhardt Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 68. Zavante Therapeutics Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2020-2025)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Coronary Imaging Catheter Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32P14840

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Digital Platform for Chronic Kidney Disease (CKD) Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-20V18395

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Continuous Glucose Monitoring Sensor Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32G20014

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9U20281

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-18H13280

Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Research Report 2025

FEATURED COMPANIES

Ventilator Associated Pneumonia (VAP) Therapeutics Market Size

Ventilator Associated Pneumonia (VAP) Therapeutics Market

Scope of Ventilator Associated Pneumonia (VAP) Therapeutics Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Ventilator Associated Pneumonia (VAP) Therapeutics Market report?

What are the Application segmentation covered in the Ventilator Associated Pneumonia (VAP) Therapeutics Market report?

What are the Type segmentation covered in the Ventilator Associated Pneumonia (VAP) Therapeutics Market report?

FEATURED COMPANIES

RELATED REPORTS